Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq
Capping a downward spiral since joining the Nasdaq biotech gold rush in 2014, Bioblast will serve as the shell for the reverse merger of fellow Israeli biotech Enlivex Therapeutics.
Enlivex will claim both the name and the executive ranks of the combined company, in addition to taking over the board of directors, and trade under a new ticker symbol. Current Enlivex equity holders are expected to own 96% of the new entity, while Bioblast shareholders split the remaining 4%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
